Answers are grounded in this paper and cite their sources.
The aim of this study was to determine the effectiveness and safety of oral linezolid as treatment of primary or secondary bloodstream infection. A retrospective observational analysis was completed on all patients who received at least 7 days of oral linezolid between June 2000 and December 2002. Twenty-four patients received 25 courses of oral linezolid for bloodstream infections. Microbiologic cure was documented in 21 (84%) of 25 patients who received at least 7 days of therapy. The most common adverse event was thrombocytopenia (13%). Orally administered linezolid offers the clinician an alternative to parenteral therapy for serious gram-positive coccal infections. A wide margin of safety was noted when therapy was limited to a mean of 14 days.
No takes yet. Share an insight, caveat, or question.
Cannon et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: